Epstein-Barr Virus (EBV) Genome and Expression in Breast Cancer Tissue: Effect of EBV Infection of Breast Cancer Cells on Resistance to Paclitaxel (Taxol)

ABSTRACT The Epstein-Barr virus (EBV) has been detected in subsets of breast cancers. In order to elaborate on these observations, we quantified by real-time PCR (Q-PCR) the EBV genome in biopsy specimens of breast cancer tissue as well as in tumor cells isolated by microdissection. Our findings show that EBV genomes can be detected by Q-PCR in about half of tumor specimens, usually in low copy numbers. However, we also found that the viral load is highly variable from tumor to tumor. Moreover, EBV genomes are heterogeneously distributed in morphologically identical tumor cells, with some clusters of isolated tumor cells containing relatively high genome numbers while other tumor cells isolated from the same specimen may be negative for EBV DNA. Using reverse transcription-PCR, we detected EBV gene transcripts: EBNA-1 in almost all of the EBV-positive tumors and RNA of the EBV oncoprotein LMP-1 in a smaller subset of the tissues analyzed. Moreover, BARF-1 RNA was detected in half of the cases studied. Furthermore, we observed that in vitro EBV infection of breast carcinoma cells confers resistance to paclitaxel (taxol) and provokes overexpression of a multidrug resistance gene (MDR1). Consequently, even if a small number of breast cancer cells are EBV infected, the impact of EBV infection on the efficiency of anticancer treatment might be of importance.

[1]  J. Zalcberg,et al.  Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs , 2005, Oncogene.

[2]  M. Newton,et al.  Lack of Association between EBV and Breast Carcinoma , 2005, Cancer Epidemiology Biomarkers & Prevention.

[3]  M. Yohe,et al.  Fatty Acid Synthase Expression Is Induced by the Epstein-Barr Virus Immediate-Early Protein BRLF1 and Is Required for Lytic Viral Gene Expression , 2004, Journal of Virology.

[4]  S. D. Hayward,et al.  Lytic Viral Replication as a Contributor to theDetection of Epstein-Barr Virus in BreastCancer , 2003, Journal of Virology.

[5]  Fabien Calvo,et al.  Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. , 2003, Cancer research.

[6]  Susan Band Horwitz,et al.  Mechanisms of Taxol resistance related to microtubules , 2003, Oncogene.

[7]  T. Turpeenniemi‐Hujanen,et al.  Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma , 2003, British Journal of Cancer.

[8]  L. Young,et al.  Epstein–Barr virus and oncogenesis: from latent genes to tumours , 2003, Oncogene.

[9]  B E Griffin,et al.  Epstein–Barr virus gene expression in human breast cancer: protagonist or passenger? , 2003, British Journal of Cancer.

[10]  Andrew Bell,et al.  Reactivity with A monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome. , 2003, Cancer research.

[11]  J. Pagano,et al.  Epstein-Barr virus induces invasion and metastasis factors. , 2003, Anticancer research.

[12]  L. Young,et al.  Lack of evidence for an association of Epstein–Barr virus infection with breast carcinoma – authors' response , 2003, Breast Cancer Research.

[13]  M. Raphaël,et al.  Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines. , 2003, The Journal of general virology.

[14]  S. Raguz,et al.  P-glycoprotein (MDR1) Expression in Leukemic Cells Is Regulated at Two Distinct Steps, mRNA Stabilization and Translational Initiation* , 2003, The Journal of Biological Chemistry.

[15]  G. Niedobitek,et al.  Lack of evidence for an association of Epstein–Barr virus infection with breast carcinoma , 2002, Breast Cancer Research.

[16]  T. Yoshizaki,et al.  Epstein-barr virus latent membrane protein 1 induces and causes release of fibroblast growth factor-2. , 2002, Cancer research.

[17]  U. Lehmann,et al.  Marked Intratumoral Heterogeneity of c-myc and CyclinD1 But Not of c-erbB2 Amplification in Breast Cancer , 2002, Laboratory Investigation.

[18]  R. Longnecker,et al.  Lack of Expression of the Epstein-Barr Virus (EBV) Gene Products, EBERs, EBNA1, LMP1, and LMP2A, in Breast Cancer Cells , 2002, Laboratory Investigation.

[19]  S. Tsutsui,et al.  EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[20]  K. Brengel-Pesce,et al.  Routine use of real‐time quantitative PCR for laboratory diagnosis of Epstein‐Barr virus infections , 2002, Journal of medical virology.

[21]  P. Chu,et al.  No significant association of Epstein-Barr virus infection with invasive breast carcinoma. , 2001, The American journal of pathology.

[22]  T. Yoshizaki,et al.  Induction of cyclooxygenase-2 by Epstein–Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Inman,et al.  Activators of the Epstein-Barr Virus Lytic Program Concomitantly Induce Apoptosis, but Lytic Gene Expression Protects from Cell Death , 2001, Journal of Virology.

[24]  F. Spyratos,et al.  Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas , 2001, British Journal of Cancer.

[25]  K. Kuroiwa,et al.  MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  F. Révillion,et al.  Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  E. Kremmer,et al.  Detection of Epstein-Barr virus in invasive breast cancers. , 1999, Journal of the National Cancer Institute.

[28]  W. Kaufmann,et al.  The Epstein-Barr Virus Protein BRLF1 Activates S Phase Entry through E2F1 Induction , 1999, Journal of Virology.

[29]  T. Yoshizaki,et al.  Matrix metalloproteinase 9 is induced by the Epstein–Barr virus BZLF1 transactivator , 1999, Clinical & Experimental Metastasis.

[30]  K. Takada,et al.  Cell-to-Cell Contact as an Efficient Mode of Epstein-Barr Virus Infection of Diverse Human Epithelial Cells , 1998, Journal of Virology.

[31]  D. Martel-Renoir,et al.  Amino‐acid change in the Epstein‐Barr‐virus zebra protein in undifferentiated nasopharyngeal carcinomas from Europe and North Africa , 1998, International journal of cancer.

[32]  E. Kremmer,et al.  IN SITU DETECTION OF THE EPSTEIN–BARR VIRUS‐ENCODED NUCLEAR ANTIGEN 1 IN ORAL HAIRY LEUKOPLAKIA AND VIRUS‐ASSOCIATED CARCINOMAS , 1996, The Journal of pathology.

[33]  S. Shousha,et al.  Presence of epstein-barr-virus in breast-carcinoma. , 1995, International journal of oncology.

[34]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[35]  Q. Zhang,et al.  Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency , 1994, Molecular and cellular biology.

[36]  M. Blanar,et al.  The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B , 1994, Molecular and cellular biology.

[37]  D. Martel-Renoir,et al.  Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. , 1993, Virology.

[38]  M. Blankenstein Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols , 1990, Breast Cancer Research and Treatment.

[39]  J. Lawrence,et al.  Sensitive, high-resolution chromatin and chromosome mapping in situ: Presence and orientation of two closely integrated copies of EBV in a lymphoma line , 1988, Cell.

[40]  S Friedman,et al.  The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Brigden,et al.  Multiple microsample analysis of intratumor estrogen receptor distribution in breast cancers by a combined biochemical/immunohistochemical method. , 1987, European journal of cancer & clinical oncology.

[42]  U. Landegren Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. , 1984, Journal of immunological methods.

[43]  M. Olivé,et al.  Breast tumor cell lines from pleural effusions. , 1974, Journal of the National Cancer Institute.

[44]  E. Kieff Epstein-Barr virus and its replication , 1996 .

[45]  B E Griffin,et al.  Epstein-Barr virus in epithelial cell tumors: a breast cancer study. , 1995, Cancer research.

[46]  M. Blanar,et al.  The bZIP Transactivator of Epstein-Barr Virus, BZLF1, Functionally and Physically Interacts with the p65 Subunit of NF-KB , 2022 .